ID   UCHL3_HUMAN             Reviewed;         230 AA.
AC   P15374; B2R970; Q5TBK8; Q6IBE9;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   28-JUN-2023, entry version 210.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase isozyme L3;
DE            Short=UCH-L3;
DE            EC=3.4.19.12 {ECO:0000269|PubMed:15157086, ECO:0000269|PubMed:15531586, ECO:0000269|PubMed:19047059, ECO:0000269|PubMed:20380862, ECO:0000269|PubMed:2530630, ECO:0000269|PubMed:9790970};
DE   AltName: Full=Ubiquitin thioesterase L3;
GN   Name=UCHL3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=2530630; DOI=10.1126/science.2530630;
RA   Wilkinson K.D., Lee K., Deshpande S., Duerksen-Hughes P., Boss J.M.,
RA   Pohl J.;
RT   "The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal
RT   hydrolase.";
RL   Science 246:670-673(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, ENZYME ACTIVITY, TISSUE SPECIFICITY, AND MUTAGENESIS OF CYS-95.
RX   PubMed=9790970; DOI=10.1006/bbrc.1998.9532;
RA   Wada H., Kito K., Caskey L.S., Yeh E.T.H., Kamitani T.;
RT   "Cleavage of the C-terminus of NEDD8 by UCH-L3.";
RL   Biochem. Biophys. Res. Commun. 251:688-692(1998).
RN   [9]
RP   IDENTIFICATION AS TUMOR-ASSOCIATED ANTIGEN BY MASS SPECTROMETRY.
RX   PubMed=14595809; DOI=10.1002/pmic.200300594;
RA   Nam M.J., Madoz-Gurpide J., Wang H., Lescure P., Schmalbach C.E., Zhao R.,
RA   Misek D.E., Kuick R., Brenner D.E., Hanash S.M.;
RT   "Molecular profiling of the immune response in colon cancer using protein
RT   microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase
RT   L3.";
RL   Proteomics 3:2108-2115(2003).
RN   [10]
RP   CATALYTIC ACTIVITY, AND SUBSTRATE SPECIFICITY.
RX   PubMed=15157086; DOI=10.1021/bi049722j;
RA   Mason D.E., Ek J., Peters E.C., Harris J.L.;
RT   "Substrate profiling of deubiquitin hydrolases with a positional scanning
RT   library and mass spectrometry.";
RL   Biochemistry 43:6535-6544(2004).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   CATALYTIC ACTIVITY.
RX   PubMed=19047059; DOI=10.1074/jbc.m807172200;
RA   Popp M.W., Artavanis-Tsakonas K., Ploegh H.L.;
RT   "Substrate filtering by the active site crossover loop in UCHL3 revealed by
RT   sortagging and gain-of-function mutations.";
RL   J. Biol. Chem. 284:3593-3602(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH UBIQUITIN, FUNCTION,
RP   ACTIVITY REGULATION, AND MUTAGENESIS OF ASP-33 AND CYS-95.
RX   PubMed=19154770; DOI=10.1016/j.neuint.2008.12.013;
RA   Setsuie R., Sakurai M., Sakaguchi Y., Wada K.;
RT   "Ubiquitin dimers control the hydrolase activity of UCH-L3.";
RL   Neurochem. Int. 54:314-321(2009).
RN   [15]
RP   ENZYME ACTIVITY, AND MUTAGENESIS OF ASP-33 AND CYS-95.
RX   PubMed=20380862; DOI=10.1016/j.neuint.2010.03.021;
RA   Setsuie R., Suzuki M., Tsuchiya Y., Wada K.;
RT   "Skeletal muscles of Uchl3 knockout mice show polyubiquitinated protein
RT   accumulation and stress responses.";
RL   Neurochem. Int. 56:911-918(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   FUNCTION.
RX   PubMed=21762696; DOI=10.1016/j.febslet.2011.06.037;
RA   Dennissen F.J., Kholod N., Hermes D.J., Kemmerling N., Steinbusch H.W.,
RA   Dantuma N.P., van Leeuwen F.W.;
RT   "Mutant ubiquitin (UBB(+1)) associated with neurodegenerative disorders is
RT   hydrolyzed by ubiquitin C-terminal hydrolase L3 (UCH-L3).";
RL   FEBS Lett. 585:2568-2574(2011).
RN   [18]
RP   FUNCTION, AND LINKAGE SPECIFICITY.
RX   PubMed=22689415; DOI=10.1002/cbic.201200261;
RA   Iphofer A., Kummer A., Nimtz M., Ritter A., Arnold T., Frank R.,
RA   van den Heuvel J., Kessler B.M., Jansch L., Franke R.;
RT   "Profiling ubiquitin linkage specificities of deubiquitinating enzymes with
RT   branched ubiquitin isopeptide probes.";
RL   ChemBioChem 13:1416-1420(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX   PubMed=9233788; DOI=10.1093/emboj/16.13.3787;
RA   Johnston S.C., Larsen C.N., Cook W.J., Wilkinson K.D., Hill C.P.;
RT   "Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8-A
RT   resolution.";
RL   EMBO J. 16:3787-3796(1997).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) IN COMPLEX WITH UBIQUITIN
RP   VINYLMETHYLESTER, AND ENZYME ACTIVITY.
RX   PubMed=15531586; DOI=10.1074/jbc.m410770200;
RA   Misaghi S., Galardy P.J., Meester W.J.N., Ovaa H., Ploegh H.L., Gaudet R.;
RT   "Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide
RT   substrate.";
RL   J. Biol. Chem. 280:1512-1520(2005).
CC   -!- FUNCTION: Deubiquitinating enzyme (DUB) that controls levels of
CC       cellular ubiquitin through processing of ubiquitin precursors and
CC       ubiquitinated proteins. Thiol protease that recognizes and hydrolyzes a
CC       peptide bond at the C-terminal glycine of either ubiquitin or NEDD8.
CC       Has a 10-fold preference for Arg and Lys at position P3'', and exhibits
CC       a preference towards 'Lys-48'-linked ubiquitin chains. Deubiquitinates
CC       ENAC in apical compartments, thereby regulating apical membrane
CC       recycling. Indirectly increases the phosphorylation of IGFIR, AKT and
CC       FOXO1 and promotes insulin-signaling and insulin-induced adipogenesis.
CC       Required for stress-response retinal, skeletal muscle and germ cell
CC       maintenance. May be involved in working memory. Can hydrolyze UBB(+1),
CC       a mutated form of ubiquitin which is not effectively degraded by the
CC       proteasome and is associated with neurogenerative disorders.
CC       {ECO:0000269|PubMed:19154770, ECO:0000269|PubMed:21762696,
CC       ECO:0000269|PubMed:22689415, ECO:0000269|PubMed:2530630,
CC       ECO:0000269|PubMed:9790970}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:15157086,
CC         ECO:0000269|PubMed:15531586, ECO:0000269|PubMed:19047059,
CC         ECO:0000269|PubMed:20380862, ECO:0000269|PubMed:2530630,
CC         ECO:0000269|PubMed:9790970};
CC   -!- ACTIVITY REGULATION: Inhibited by monoubiquitin and diubiquitin.
CC       {ECO:0000269|PubMed:19154770}.
CC   -!- SUBUNIT: Preferentially binds diubiquitin; the interaction does not
CC       hydrolyze diubiquitin but, in vitro, inhibits the hydrolyzing activity
CC       on other substrates. {ECO:0000269|PubMed:15531586}.
CC   -!- INTERACTION:
CC       P15374; G5E9A7: DMWD; NbExp=3; IntAct=EBI-954554, EBI-10976677;
CC       P15374; Q15797: SMAD1; NbExp=2; IntAct=EBI-954554, EBI-1567153;
CC       P15374; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-954554, EBI-5235340;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, skeletal muscle, and
CC       testis. {ECO:0000269|PubMed:9790970}.
CC   -!- MISCELLANEOUS: Identified as a tumor-specific antigen in colon cancer.
CC   -!- SIMILARITY: Belongs to the peptidase C12 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M30496; AAA36791.1; -; mRNA.
DR   EMBL; BT019359; AAV38166.1; -; mRNA.
DR   EMBL; CR456855; CAG33136.1; -; mRNA.
DR   EMBL; AK313665; BAG36417.1; -; mRNA.
DR   EMBL; AL137244; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471093; EAW80542.1; -; Genomic_DNA.
DR   EMBL; BC018125; AAH18125.1; -; mRNA.
DR   CCDS; CCDS9453.1; -.
DR   PIR; A40085; A40085.
DR   RefSeq; NP_001257881.1; NM_001270952.1.
DR   RefSeq; NP_005993.1; NM_006002.4.
DR   PDB; 1UCH; X-ray; 1.80 A; A=1-230.
DR   PDB; 1XD3; X-ray; 1.45 A; A/C=1-230.
DR   PDB; 6ISU; X-ray; 1.87 A; A=1-230.
DR   PDB; 6QML; X-ray; 2.10 A; A/D=4-230.
DR   PDBsum; 1UCH; -.
DR   PDBsum; 1XD3; -.
DR   PDBsum; 6ISU; -.
DR   PDBsum; 6QML; -.
DR   AlphaFoldDB; P15374; -.
DR   BMRB; P15374; -.
DR   SMR; P15374; -.
DR   BioGRID; 113194; 173.
DR   DIP; DIP-29135N; -.
DR   IntAct; P15374; 19.
DR   MINT; P15374; -.
DR   STRING; 9606.ENSP00000366819; -.
DR   BindingDB; P15374; -.
DR   ChEMBL; CHEMBL6195; -.
DR   DrugCentral; P15374; -.
DR   GuidetoPHARMACOLOGY; 2427; -.
DR   MEROPS; C12.003; -.
DR   GlyGen; P15374; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P15374; -.
DR   MetOSite; P15374; -.
DR   PhosphoSitePlus; P15374; -.
DR   BioMuta; UCHL3; -.
DR   DMDM; 136682; -.
DR   OGP; P15374; -.
DR   REPRODUCTION-2DPAGE; IPI00011250; -.
DR   EPD; P15374; -.
DR   jPOST; P15374; -.
DR   MassIVE; P15374; -.
DR   MaxQB; P15374; -.
DR   PaxDb; P15374; -.
DR   PeptideAtlas; P15374; -.
DR   ProteomicsDB; 53133; -.
DR   Antibodypedia; 10104; 462 antibodies from 40 providers.
DR   DNASU; 7347; -.
DR   Ensembl; ENST00000377595.8; ENSP00000366819.3; ENSG00000118939.18.
DR   GeneID; 7347; -.
DR   KEGG; hsa:7347; -.
DR   MANE-Select; ENST00000377595.8; ENSP00000366819.3; NM_006002.5; NP_005993.1.
DR   UCSC; uc001vjq.5; human.
DR   AGR; HGNC:12515; -.
DR   CTD; 7347; -.
DR   DisGeNET; 7347; -.
DR   GeneCards; UCHL3; -.
DR   HGNC; HGNC:12515; UCHL3.
DR   HPA; ENSG00000118939; Low tissue specificity.
DR   MIM; 603090; gene.
DR   neXtProt; NX_P15374; -.
DR   OpenTargets; ENSG00000118939; -.
DR   PharmGKB; PA37162; -.
DR   VEuPathDB; HostDB:ENSG00000118939; -.
DR   eggNOG; KOG1415; Eukaryota.
DR   GeneTree; ENSGT00940000154925; -.
DR   HOGENOM; CLU_054406_1_1_1; -.
DR   InParanoid; P15374; -.
DR   OMA; EFTADHQ; -.
DR   OrthoDB; 179179at2759; -.
DR   PhylomeDB; P15374; -.
DR   TreeFam; TF316166; -.
DR   BRENDA; 3.4.19.12; 2681.
DR   PathwayCommons; P15374; -.
DR   Reactome; R-HSA-5689603; UCH proteinases.
DR   Reactome; R-HSA-8866652; Synthesis of active ubiquitin: roles of E1 and E2 enzymes.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   SABIO-RK; P15374; -.
DR   SignaLink; P15374; -.
DR   SIGNOR; P15374; -.
DR   BioGRID-ORCS; 7347; 9 hits in 1202 CRISPR screens.
DR   ChiTaRS; UCHL3; human.
DR   EvolutionaryTrace; P15374; -.
DR   GeneWiki; UCHL3; -.
DR   GenomeRNAi; 7347; -.
DR   Pharos; P15374; Tchem.
DR   PRO; PR:P15374; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P15374; protein.
DR   Bgee; ENSG00000118939; Expressed in right adrenal gland and 114 other tissues.
DR   ExpressionAtlas; P15374; baseline and differential.
DR   Genevisible; P15374; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0004843; F:cysteine-type deubiquitinase activity; IDA:UniProtKB.
DR   GO; GO:0019784; F:deNEDDylase activity; TAS:Reactome.
DR   GO; GO:0008233; F:peptidase activity; IDA:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0030163; P:protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:Reactome.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   CDD; cd09616; Peptidase_C12_UCH_L1_L3; 1.
DR   Gene3D; 3.40.532.10; Peptidase C12, ubiquitin carboxyl-terminal hydrolase; 1.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR001578; Peptidase_C12_UCH.
DR   InterPro; IPR036959; Peptidase_C12_UCH_sf.
DR   PANTHER; PTHR10589; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE; 1.
DR   PANTHER; PTHR10589:SF24; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE ISOZYME L3; 1.
DR   Pfam; PF01088; Peptidase_C12; 1.
DR   PRINTS; PR00707; UBCTHYDRLASE.
DR   SUPFAM; SSF54001; Cysteine proteinases; 1.
DR   PROSITE; PS00140; UCH_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasm; Hydrolase; Phosphoprotein; Protease;
KW   Reference proteome; Thiol protease; Ubl conjugation pathway.
FT   CHAIN           1..230
FT                   /note="Ubiquitin carboxyl-terminal hydrolase isozyme L3"
FT                   /id="PRO_0000211061"
FT   REGION          8..13
FT                   /note="Interaction with ubiquitin"
FT                   /evidence="ECO:0000269|PubMed:15531586"
FT   REGION          152..159
FT                   /note="Interaction with ubiquitin. Crossover loop which
FT                   restricts access of large ubiquitin adducts to the active
FT                   site"
FT                   /evidence="ECO:0000269|PubMed:15531586,
FT                   ECO:0000269|PubMed:19047059"
FT   REGION          219..224
FT                   /note="Interaction with ubiquitin"
FT                   /evidence="ECO:0000269|PubMed:15531586"
FT   ACT_SITE        95
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000269|PubMed:19154770,
FT                   ECO:0000269|PubMed:20380862, ECO:0000269|PubMed:9790970"
FT   ACT_SITE        169
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250|UniProtKB:P09936"
FT   SITE            184
FT                   /note="Important for enzyme activity"
FT                   /evidence="ECO:0000250|UniProtKB:P09936"
FT   MOD_RES         130
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MUTAGEN         33
FT                   /note="D->A: Decreased interaction with diubiquitin. No
FT                   accumulation of free diubiquitin. Decreased levels of
FT                   polyubiquitinated lysozyme."
FT                   /evidence="ECO:0000269|PubMed:19154770,
FT                   ECO:0000269|PubMed:20380862"
FT   MUTAGEN         95
FT                   /note="C->A: Increased interaction with diubiquitin."
FT                   /evidence="ECO:0000269|PubMed:19154770,
FT                   ECO:0000269|PubMed:20380862, ECO:0000269|PubMed:9790970"
FT   MUTAGEN         95
FT                   /note="C->S: Abolishes enzymatic activity. Increased
FT                   interaction with diubiquitin."
FT                   /evidence="ECO:0000269|PubMed:19154770,
FT                   ECO:0000269|PubMed:20380862, ECO:0000269|PubMed:9790970"
FT   STRAND          9..11
FT                   /evidence="ECO:0007829|PDB:6QML"
FT   HELIX           13..22
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   STRAND          29..33
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   HELIX           39..42
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   STRAND          49..57
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   HELIX           60..76
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   HELIX           92..94
FT                   /evidence="ECO:0007829|PDB:1UCH"
FT   HELIX           95..105
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   HELIX           106..110
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   HELIX           118..126
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   HELIX           131..139
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   HELIX           142..152
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   STRAND          155..157
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   STRAND          168..176
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   STRAND          179..183
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   STRAND          187..189
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   STRAND          191..195
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   TURN            198..200
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   HELIX           201..215
FT                   /evidence="ECO:0007829|PDB:1XD3"
FT   STRAND          223..229
FT                   /evidence="ECO:0007829|PDB:1XD3"
SQ   SEQUENCE   230 AA;  26183 MW;  8ACACE6E1D86FD55 CRC64;
     MEGQRWLPLE ANPEVTNQFL KQLGLHPNWQ FVDVYGMDPE LLSMVPRPVC AVLLLFPITE
     KYEVFRTEEE EKIKSQGQDV TSSVYFMKQT ISNACGTIGL IHAIANNKDK MHFESGSTLK
     KFLEESVSMS PEERARYLEN YDAIRVTHET SAHEGQTEAP SIDEKVDLHF IALVHVDGHL
     YELDGRKPFP INHGETSDET LLEDAIEVCK KFMERDPDEL RFNAIALSAA
//
